Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events

Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée à la COVID-19

Résumé en anglais

To investigate immune checkpoint inhibitors (ICIs) induced pancreatic injury (ICIPI), the prognostic effect of COVID-19 vaccine on cancer patients, and whether COVID-19 vaccine increases the incidence of ICIPI. We conducted a retrospective study of 256 stage IV cancer patients treated with ICIs at The First Affiliated Hospital of Anhui Medical University from January 2020 to November 2022. Data collected included pancreatic enzyme levels, treatment outcomes, and vaccination status. Statistical significance was determined using the ?2 test and Kaplan-Meier method (p?<?.05). Compared to the control group, the vaccinated group (p?<?.0001) and the group with elevated pancreatic enzyme levels (p?=?.044) demonstrated higher disease control rates, indicating a direct benefit of vaccination and enzyme monitoring on treatment outcomes. Additionally, vaccinated patients demonstrated longer overall survival versus unvaccinated patients (23.9?months [95% CI, 22.3?25.5] vs 23.6?months [95% CI, 21.1?26.2], HR?=?0.45 [95% CI, 0.24?0.86], p?=?.015) and progression-free survival (17.2?months [95% CI, 14.3?20.1] vs 13.7?months [95% CI, 11.3?16.1], HR?=?0.54 [95% CI, 0.36?0.82], p?=?.004). Importantly, the analysis revealed no significant association between vaccination and pancreatic injury (p?=?.46). Monitoring pancreatic enzymes can effectively evaluate the therapeutic impact in patients using ICIs. Patients vaccinated against COVID-19 experience better immunotherapy outcomes without an increased risk of ICIPI.